Ghana Active Wound Care Market

Ghana Active Wound Care Market Outlook 2035

• Ghana active wound care industry was valued at US$ 663.8 Thousand in 2024
• It is projected to grow at a CAGR of 2.2% from 2025 to 2035 and cross US$ 863.0 Thousand by the end of 2035

Analysts’ Viewpoint regarding Ghana Active Wound Care Market

Increasing incidences of chronic wounds commonly associated with diseases like diabetes and hypertension, higher levels of awareness of advanced wound care products such as dressings and bioactive materials among patients and healthcare professionals, improved Ghanaian health infrastructures, and influx of multinational and local players providing innovative wound care products are the primary drivers to Ghana active wound care market.

In addition, increased public and private funding for health programs combined with an elevated use of telemedicine and electronic health platforms is enhancing patient management and follow-up care.

Rise in demand for advanced wound management solutions necessitates modern therapies that are capable of stimulating healing and lowering infection rates. With growing awareness about cutting-edge wound care products, the market for skin-substitutes and bioactive materials is poised to escalate.

In addition, there is an increased focus on training and education among healthcare workers. Most of the clinics and hospitals are spending money on workshops and seminars to enlighten the staff members on new wound care products and processes. Capacity building is important so that health professionals are well equipped to handle advanced wound care solutions proficiently, thereby leading to improved patient outcomes.

Ghana Active Wound Care Market Introduction

Active wound care is an essential component of modern healthcare, which is intended to manage and control wounds and induce healing and prevent complications. Unlike passive, traditional wound care methods, which may consist of mere cleansing and dressing, active wound care employs more sophisticated therapeutic agents for better outcomes and faster healing. This need is prompted by the rising prevalence of chronic wounds due to diseases like diabetes, obesity, and vascular disorders.

Chronic wounds are issues of complexity in the patient population, causing immense suffering and pain, rise in the healthcare cost related to them, and infection risk.

Biomaterials have an important role to play among active wound care agents, thereby providing materials intended for interaction with biological systems to promote healing by imitating the normal environment of the skin. Biomaterials are made from natural or synthetic products and can be used in hydrogels, foams, and films. These active agents provide a moist wound environment, which can be essential for optimal healing, and can be used as barriers to prevent infection.

Skin substitutes are also an active component of novel wound care. They are man-made or biological products with the purpose of replacing or supporting missing skin. Human and animal tissue-based biological substitutes provide a scaffold upon which tissue can grow, whereas synthetic substitutes form an impermanent barrier to allow healing. The use of skin substitutes is especially beneficial for those with wide or complex wounds as not only do they aid in the healing process but also the regaining of the integrity and function of the skin.

Growth factors are also important in active wound care by stimulating the body's own repair mechanisms. These proteins are employed in cellular functions such as cell proliferation, migration, and differentiation. The use of growth factors on the wound can cause stimulation of the repair processes with the effect that there is increased growth of granulation tissue and angiogenesis, or the formation of new blood vessels. This is useful in the healing of chronic wounds, in which these processes are normally lacking.

Rising Incidence of Chronic Wounds Anticipated to Boost Ghana Active Wound Care Market Share

The increasing incidences of chronic wounds in Ghana is one of the major forces driving Ghana active wound care market, as such a situation is a reflection of the overall health problem and demographic change occurring in Ghana. Chronic wounds, as commonly defined, are those wounds that do not heal within a reasonable time would be predominantly diabetes-related wounds, venous insufficiency, and pressure ulcers.

In Ghana, the increase in non-communicable diseases (NCDs), especially diabetes and hypertension, are the main contributors to chronic wound prevalence.

For instance, an article published recently in PubMed Central stated that the prevalence of diabetic foot ulcer in Ghana ranged between 3.8% and 11%, while nearly 6-23%of these ulcers are vulnerable to worsening, eventually leading to amputation. Another study reported Ghana to be the second most endemic Buruli ulcer-prone country with 17% of the global disease burden.

Furthermore, the aging population in Ghana is another important consideration accelerating the prevalence of chronic wounds. As the population ages, the risk of developing a wound increase significantly due to loss of elasticity of the skin, loss of blood supply, and pre-existing medical conditions that affect healing process.

Estimates from Ghana Statistical Service (GSS) reveals that the elderly population in the country has increased by a factor of 10 over the past six decades, with 213,477 individuals in 1960 to 1,991,736 in 2021.

Healthcare Infrastructure Development to Drive Ghana Active Wound Care Market Expansion

Expansion of medical centers in Ghana is a powerful driver to the thriving wound care market, reflecting national interest in enhancing health results and accessibility of healthcare for the populace. Ghana has invested significantly in recent times into healthcare facilities and health worker training in equipment to enhance standards of care. Infrastructure development is particularly salient for wound care since chronic wound management requires both - high-end capabilities and healthcare environments that are adequately designed for the technologies used for assessments to work optimally.

In April 2025, Czech President Petr Pavel inaugurated a new hospital on the outskirts of Accra, Ghana, built by Czech company Vamed Health Projects. The hospital has 40 beds and is supposed to cater to a population of 100,000 individuals. The hospital is part of the construction of 12 health centers in the other districts across Ghana.

Additionally, in April 2025, the Ghanaian Government announced several initiatives to strengthen the country’s healthcare system. For instance, it has announced Mahama Cares, a social initiative spearheaded by Ghanaian President John Dramani Mahama to bridge healthcare financing gaps by introducing the Ghana Medical Care Trust Fund. The fund is intended to be utilized to support treatment of individuals battling lifestyle and the other non-communicable diseases such as kidney failure (dialysis), cancers, sickle cell disease, diabetes, hypertension, and heart disease.

Biomaterials Leading Ghana Active Wound Care Market

The biomaterials segment is dominating due to the ability of biomaterials to stimulate tissue regeneration and healing of the wound. Biomaterials can be either natural or synthetic but are specifically engineered to enhance the healing process by mimicking the structure and function of human tissue. They can be applied across all types of wounds ranging from surgical wounds to chronic ulcers and are thus the most sought-after products by healthcare professionals.

Chronic Wound Captures Majority Share in Ghana Active Wound Care Market

The chronic wound segment records the highest percentage of Ghana active wound care market, which is a reflection of an emerging public health issue. Chronic wounds such as diabetic ulcers, venous leg ulcers, and pressure sores usually stem from existing health conditions and can potentially severely degrade the quality of life of patients.

In Ghana, the increasing rate of diabetes and vascular disorders has increased the incidence of chronic wounds, and there exists a demand for effective treatment. The excellence of this segment is due to the complexity and chronicity of chronic wounds, which make them require specialized management and sophisticated wound care techniques.

Analysis of Key Players in Ghana Active Wound Care Market

The leading players in Ghana active wound care market are investing in training initiatives and workshops among healthcare professionals. The move is intended to enhance knowledge and skills in wound management to support practitioners in easily implementing new products and technology. Various institutions, for instance, are carrying out sensitization activities to educate patients and communities about wound care and seeking immediate treatment.

Smith+Nephew, Johnson & Johnson Services, Inc., Solventum, Organogenesis Inc., and Convatec are some of the leading players operating in Ghana active wound care market.

Each of these players have been have been profiled in Ghana active wound care market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in Ghana Active Wound Care Market

• In April 2025, Abeona Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) had approved ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The FDA approval of ZEVASKYN is based on the pivotal Phase 3 VIITAL study (NCT04227106), a multi-center, randomized, intrapatient-controlled trial that met its two co-primary efficacy endpoints.
• In February 2025, the U.S. FDA granted breakthrough therapy designation to SkinTE for the treatment of Wagner grade 1 diabetic foot ulcers (DFUs). The designation was supported by data from a phase 2 (NCT03881254) multicenter, randomized, controlled trial. Results of the study demonstrated that by 12 weeks, there were significantly more wound closures in the experimental group (35 of 50 patients) than in the control group (17 of 50 patients). For the secondary end point of percentage area reduction, the experimental group had a greater percentage at 80.7% as compared to the control group at 26.8% over 8 weeks.
• In August 2024, Vericel Corporation announced that the U.S. Food and Drug Administration (FDA) approved a pediatric indication for NexoBrid (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The approval was based on results of a global Phase 3 clinical trial, Children Innovation Debridement Study (CIDS), which evaluated the safety and efficacy of NexoBrid in hospitalized pediatric patients, as well as additional pediatric data available from Phase 3 and Phase 2 studies conducted during the clinical development of NexoBrid.

Ghana Active Wound Care Market Snapshot